Lynn Kramer, MD

The chief medical officer at Eisai provided context towards the ongoing initiatives to further the efficacy and safety profile of lecanemab, an FDA-approved treatment for early Alzheimer disease. [WATCH TIME: 3 minutes]

This is the first large late-stage clinical trial to further support the amyloid hypothesis.